Sign up to Forward: news, insights and features from Mewburn Ellis
Ever since the UK announced its intended departure from the European Union, there has been much speculation about what model of exhaustion would be adopted and the impact it would have on the pharmaceutical industry. Following a recent consultation by the UK government, we have a greater understanding of what the future of parallel trade in the UK might look like
In our special report, we look at the outcome of the consultation and what this means for pharmaceutical trade mark owners. We explore the established law and practice on parallel imports, with a particular focus on practical examples of how it applies.
To receive a copy of the report, please complete the form on the right.